Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer.
- Author:
Feng LIU
1
;
Bin JIANG
;
Sheng-ji GONG
;
Bao-di YAO
;
Wen-ying ZHANG
;
Guan-shan ZHU
;
Zhong-zheng ZHU
;
Yu-fang GONG
;
Mei-ling WANG
;
Xiao-hua HU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; genetics; DNA Mutational Analysis; Female; Genes, ras; genetics; Humans; Lung Neoplasms; drug therapy; genetics; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; therapeutic use; Receptor, Epidermal Growth Factor; genetics
- From: Chinese Journal of Medical Genetics 2007;24(1):31-34
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate gene mutations of the epidermal growth factor receptor (EGFR) and K-RAS in Chinese non-small cell lung cancers (NSCLCs).
METHODSMutations of exons 18, 19 and 21 of the EGFR and codons 12, 13 of the K-RAS in 101 NSCLCs were detected by PCR-amplifying and gene sequencing, and the relationship between mutations and clinical characters of NSCLCs and response to gefitinib were analyzed.
RESULTSOverall, 26 EGFR mutations (25.7%), 3 K-RAS mutations (2.9%) were detected, and EGFR mutation frequencies in adenocarcinomas, nonsmoker and female were found to be high (44.2%, 65.7% and 48.3% respectively). Nine out of 10 gefitinib treated patients with disease control was found with EGFR mutation.
CONCLUSIONThe data suggest that mutation frequency of EGFR in NSCLCs from Chinese patients is higher than that of western ethnicities, such mutations are well correlated with tumor response to gefitinib, and gefitinib is more fit for Chinese NSCLC patients.
